Speakers

Dr. Hongling Zhang is the director of the Division of Bioequivalence II in the Office of Bioequivalence of OGD, FDA. Since joining OGD in 2008, she has been involved in developing bioequivalence (BE) recommendations and evaluating BE studies in ANDAs for many complex drug products. She is an expert in resolving complex scientific and/or regulatory issues related to BE. In her current role, she provides scientific advice on BE standards through guidances, meetings and controlled correspondences. Dr. Zhang received her Ph.D. degree in Pharmacology from the University of South Florida and completed a post-doctoral training at the Moffitt Cancer Institute.